Evidence map›Paper›PMID 27756325›Full record

ArticleMolecular cancer2016

Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells.

Mario A Cepeda, Jacob J H Pelling, Caitlin L Evered, Karla C Williams, Zoey Freedman, Ioana Stan, Jessica A Willson, Hon S Leong, Sashko Damjanovski

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Is the endotoxin-complement cascade the major driver in lipedema?Trends in endocrinology and metabolism: TEM · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Modulation of RECK levels inJournal of biological research (Thessalonike, Greece) · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mario A CepedaDepartment of Biology, Faculty of Science, University of Western Ontario, 1151 Richmond St N., London, Ontario, N6A 5B7, Canada.
Jacob J H PellingDepartment of Biology, Faculty of Science, University of Western Ontario, 1151 Richmond St N., London, Ontario, N6A 5B7, Canada.
Caitlin L EveredDepartment of Biology, Faculty of Science, University of Western Ontario, 1151 Richmond St N., London, Ontario, N6A 5B7, Canada.
Karla C WilliamsTranslational Prostate Cancer Research Laboratory, Lawson Health Research Institute, London, ON, Canada.
Zoey FreedmanDepartment of Biology, Faculty of Science, University of Western Ontario, 1151 Richmond St N., London, Ontario, N6A 5B7, Canada.
Ioana StanDepartment of Biology, Faculty of Science, University of Western Ontario, 1151 Richmond St N., London, Ontario, N6A 5B7, Canada.
Jessica A WillsonDepartment of Biology, Faculty of Science, University of Western Ontario, 1151 Richmond St N., London, Ontario, N6A 5B7, Canada.
Hon S LeongDepartment of Surgery, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
Sashko DamjanovskiDepartment of Biology, Faculty of Science, University of Western Ontario, 1151 Richmond St N., London, Ontario, N6A 5B7, Canada. sdamjano@uwo.ca.
Western University · CALawson Health Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMembrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete.

methodsMCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo.

resultsIn 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein.

conclusionsThis study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo.

Indexed as

Gene ExpressionBreast NeoplasmsCell Line, TumorCell MovementCell SurvivalCell Transformation, NeoplasticExtracellular MatrixFemaleHumansMAP Kinase Signaling SystemMatrix Metalloproteinase 14MCF-7 CellsModels, BiologicalPhenotypeRNA, MessengerTissue Inhibitor of Metalloproteinase-2Matrix Metalloproteinase 14RNA, MessengerTissue Inhibitor of Metalloproteinase-23D cultureBreast cancerCell migrationIntravital imagingMMP-14MT1-MMP

Identifiers

PMID27756325
PMCPMC5070195
OpenAlexW2533114297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.